

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President
of Operations and Clinical Affairs
Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager
Ida Delmendo

Clinical Projects Manager
Cindy Spielvogel

Project Director
Christina Doong

Proofreader
Maggie Shaw

Associate Editor
Jeanne Linke

Clinical Editor
Michael R. Page, PharmD, RPh

Designer
Julianne Costello

Associate Publisher
Justin T. Gallagher

Director of Sales
Sara Stewart

National Account Managers
Gabrielle Consola
Michael Costella

Corporate

Chairman and CEO
Mike Hennessy, Sr

Vice Chairman
Jack Lepping

Executive Vice President,
Mergers and Acquisitions
Tighe Blazier

Chief Operating Officer
Neil Glasser, CPA/CFE

President, Managed Markets
Brian Haug

Executive Vice President
and General Manager
John Maglione

Chief Creative Officer
Jeff Brown

Vice President of Education
David Heckard

Copyright © 2015 by Managed Care
& Healthcare Communications, LLC

September 2015 – Vol. 21, No. 11, Sup.

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin- Aldosterone System Inhibitors

Table of Contents

Participating Faculty

S210

Report

- Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

S212

**Murray Epstein, MD; Nancy L. Reaven, MA; Susan E. Funk, MBA;
Karen J. McGaughey, PhD; Nina Oestreicher, PhD; John Knispel, MD**



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A579

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

This study and publication were sponsored by **Relypsa, Inc.**

...

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

This supplement to *The American Journal of Managed Care* describes a study that examined renin-angiotensin-aldosterone system (RAAS) inhibitor dose levels in a US patient population, investigated the impact of hyperkalemia on RAAS inhibitor dose, and evaluated the association between dose levels and clinical outcomes. The results show that relatively few patients were prescribed maximum doses of RAAS inhibitors, and dose and usage declined following hyperkalemia. Patients on submaximum doses or who discontinued RAAS inhibitors had worse outcomes than patients on maximum doses.

■ Faculty

Murray Epstein, MD

Professor of Medicine
Division of Nephrology and Hypertension
University of Miami Miller School of Medicine
Miami, Florida

Medical Investigator
South Florida VA Research and Education Foundation
VA Medical Center
Miami, Florida

Susan E. Funk, MBA

Senior Vice President of Data Analytics
Strategic Health Resources
La Cañada, California

John Knispel, MD

Regional Medical Director, Florida
Humana Inc
West Palm Beach, Florida

Karen J. McGaughey, PhD

Associate Professor
Department of Statistics
California Polytechnic State University
San Luis Obispo, California

Nina Oestreicher, PhD

Executive Director
Health Economics and Outcomes Research
Relypsa, Inc
Redwood City, California

Assistant Clinical Professor
University of California, San Francisco
Department of Clinical Pharmacy
San Francisco, California

Nancy L. Reaven, MA

President
Strategic Health Resources
La Cañada, California

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Murray Epstein, MD

Consultant or paid advisory board:

Bayer; OPKO Health; Relypsa, Inc

Lecture fees/meeting conference attendance:

Relypsa, Inc

Susan E. Funk, MBA

Consultant/receipt of payment for involvement in preparation of this manuscript:

Relypsa, Inc; Strategic Health Resources

John Knispel, MD

Consultant/receipt of payment for involvement in preparation of this manuscript:

Relypsa, Inc

Karen J. McGaughey, PhD

Consultant:

Relypsa, Inc; Strategic Health Resources

Nina Oestreicher, PhD

Employment/stock ownership:

Relypsa, Inc

Nancy L. Reaven, MA

Consultant:

Relypsa, Inc; Strategic Health Resources

Stock ownership:

Relypsa, Inc

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ SUPPLEMENT POLICY STATEMENT ■

Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

Publisher's Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.